Absci in the news

Absci unveiled its Phase 2 trial design for ABS-201 in endometriosis, facing a stock pullback despite significant year-to-date gains and analyst predictions of undervaluation based on its early-stage pipeline.

Absci's stock dropped, missing earnings forecasts, while institutional investments increased and analysts maintained a "Moderate Buy" rating.

Absci Corporation receives a "Moderate Buy" consensus from analysts with an average target price of $13.71, despite missing quarterly earnings and revenue estimates.

Absci unveiled its Phase 2 STORYLINE trial design for ABS-201 in endometriosis, linking its AI drug creation platform to a mid-stage clinical asset, despite current financial losses and concentration risks.

Absci is progressing ABS-201 to a global Phase 2 trial for endometriosis, with an anticipated mid-2027 start, while Needham maintains an $11 price target.

Absci plans to start a mid-stage clinical trial for its endometriosis drug candidate, ABS-201, in mid-2027.

Absci's stock price increased by 6.1% on Tuesday, with a "Moderate Buy" analyst consensus despite missing recent earnings and revenue estimates, while institutional ownership stands at 52.05%.

Absci's stock rating was reiterated by Guggenheim despite a delayed endometriosis trial, while the company also reported a larger-than-expected Q2 loss and lower revenue.

Absci Corporation recently saw Bank of America Corp DE acquire new shares, amidst mixed financial results and a "Moderate Buy" analyst rating for its AI-driven drug discovery platform.

Absci unveiled plans for its global Phase 2 STORYLINE trial for ABS-201 to treat endometriosis, highlighting its AI-driven drug creation and related investment risks.

Absci plans a Phase 2 trial for its AI-designed antibody ABS-201 for endometriosis, with initiation expected in mid-2027.

Absci is advancing its AI-driven drug ABS-201 into a Phase 2 trial for endometriosis, with its stock experiencing high volatility and a valuation debate despite being considered 29% undervalued.

Absci announced preliminary details for its Phase 2 STORYLINE trial of AI-designed antibody ABS-201 for endometriosis, aiming to assess efficacy and safety in patients with moderate to severe endometriosis-associated pain, with initiation anticipated in mid-2027.

Absci plans a Phase 2 clinical trial for ABS-201 to treat endometriosis, recruiting about 150 patients globally.

Absci Corporation provided details for its upcoming Phase 2 clinical trial of ABS-201, an AI-designed antibody for endometriosis, expected to start in mid-2027.

Absci's stock declined 8.3% despite several analysts raising price targets, while the company missed earnings estimates and saw increased institutional investment.

Absci's stock received a reaffirmed "buy" rating from Needham & Company LLC, while its recent earnings missed analyst estimates and institutional investors have adjusted their holdings.

Needham reiterated its Buy rating on Absci, highlighting its lead product candidate ABS-201 and AI-driven drug discovery approach.

Absci's stock is trading at a high premium compared to its book value, raising questions about whether its underlying assets justify the current share price.

Absci Corporation's stock has significant upside potential according to Wall Street analysts, backed by positive earnings estimate revisions and a Zacks Rank #2 (Buy).